Oxycodone CR

Phase 3Small molecule

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Oxycodone CR is one of 149 small molecule programs targeting Low back pain. It is currently in Phase 3.

Indications

Total Trials

Active Trials

148

Competitors

Pipeline

Status by Indication[3][1]

Indication

Low Back PainActive, not recruiting

Bone PainActive, not recruiting

Cancer PainActive, not recruiting

Joint DiseaseActive, not recruiting

Chronic PainActive, not recruiting

OsteoarthritisActive, not recruiting

Low Back PainPhase 3

Active, not recruiting

Bone PainPhase 3

Active, not recruiting

Cancer PainPhase 3

Active, not recruiting

Joint DiseasePhase 3

Active, not recruiting

Chronic PainPhase 3

Active, not recruiting

OsteoarthritisPhase 2

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Oxycodone CR

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

4 2

Epidiolex

Jazz Pharmaceuticals

Preclinical

4 3

Voltaren

CCerimon Pharmaceuticals

Preclinical

4 4

Chirocaine

PPurdue Pharma LP

Preclinical

1 5

Lunesta

Akero Therapeutics

Preclinical

1 6

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 7

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 8

Ansaid

PPharmacia and Upjohn

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Benadryl

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteoarthritis4 trials

Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00979953·408 enrolled

A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Completed·GGrünenthal GmbH·Phase 3·NCT00486811·990 enrolled

A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT01094262·196 enrolled

Show 1 more trial

Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

Completed·TTris Pharma, Inc.·Phase 2·NCT01709214·619 enrolled

Chronic pain1 trial

A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00361504·1,123 enrolled

Bone pain1 trial

NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers

Unknown status·MMedlab Clinical·Phase 3·NCT04808531·360 enrolled

Efficacy and Safety1 trial

An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT01205126·260 enrolled

Hip Replacement Surgery1 trial

A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00364533·367 enrolled

4 more indications

Joint Disease1 trial

A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00784277·597 enrolled

Low back pain1 trial

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00449176·981 enrolled

Cancer Pain1 trial

A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01165281·343 enrolled

Oxycodone1 trial

Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)

Completed· Endo Pharmaceuticals logo

Endo Pharmaceuticals·Phase 4·NCT00955110·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Oxycodone CR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oxycodone CR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oxycodone CR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson Pharmaceutical Research & Development, L.L.C. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Oxycodone CR

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteoarthritis4 trials

Chronic pain1 trial

Bone pain1 trial

Efficacy and Safety1 trial

Hip Replacement Surgery1 trial

Joint Disease1 trial

Low back pain1 trial

Cancer Pain1 trial

Oxycodone1 trial

References

Drug Info

Quick Facts

Related News